{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:52:57Z","timestamp":1790941977009,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":5586,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1093\/annonc\/mdh351","type":"journal-article","created":{"date-parts":[[2004,8,19]],"date-time":"2004-08-19T18:30:24Z","timestamp":1092940224000},"page":"1339-1343","source":"Crossref","is-referenced-by-count":310,"title":["Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study"],"prefix":"10.1016","volume":"15","author":[{"given":"T.","family":"Andr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Rosmorduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Provent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Maindrault-Goebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Avenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Selle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Paye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hannoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Houry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh351_bb0010","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0015","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","article-title":"Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer","volume":"54","author":"Falkson","year":"1984","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh351_bb0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/oxfordjournals.annonc.a058597","article-title":"Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study","volume":"4","author":"Taal","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0025","first-page":"948","article-title":"Chemotherapy for gallbladder carcinoma\u2014a surgeon's perspective","volume":"4","author":"Todoroki","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"10.1093\/annonc\/mdh351_bb0030","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1984.2.11.1245","article-title":"5-fluorouracil, mitomycin and doxorubicin (FAM) in carcinoma of the biliary tract","volume":"2","author":"Harvey","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0035","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1023\/A:1008241008379","article-title":"Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin","volume":"9","author":"Ducreux","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0040","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdf201","article-title":"Optimization of 5-fluorouracil\/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma","volume":"13","author":"Taieb","year":"2002","journal-title":"Ann Oncol"},{"issue":"Abstr 696","key":"10.1093\/annonc\/mdh351_bb0045","first-page":"21","article-title":"A randomized phase II trial of weekly high dose 5FU (HD-FU) with and without folinic acid (FA) and cisplatin (P) in patients (pts) with advanced biliary tract carcinoma: the EORTC 40955 trial","volume":"175a","author":"Mitry","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0050","first-page":"280","article-title":"Multicenter phase II trial of oxaliplatin plus capecitabine (XELOX) in advanced biliary system adenocarcinomas (study CCC\/CBG-01)","volume":"22","author":"Nehls","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdh351_bb0055","first-page":"S1511","article-title":"Phase II study of gemcitabine in patients with nonresectable cancer of the biliary system","volume":"35","author":"Kubicka","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 20","key":"10.1093\/annonc\/mdh351_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/sonc.2002.37375","article-title":"Chemotherapy in biliary tract carcinomas: Results in India","volume":"29","author":"Doval","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0065","first-page":"2476","article-title":"Gemcitabine in patients with nonresectable cancer of the biliary system or advanced gallbladder cancer","volume":"95","author":"Dobrila-Dintinjana","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"Abstr","key":"10.1093\/annonc\/mdh351_bb0070","article-title":"Gemcitabine (GEM) in advanced biliary tract cancer (ABTC). Experience from Chile and Argentina in phase II trials","volume":"157a","author":"Arroyo","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0075","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/annonc\/mdh096","article-title":"Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial","volume":"15","author":"Kornek","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0080","first-page":"498","article-title":"Gemcitabine for the treatment of advanced biliary tract carcinomas evaluation of two different dose regimens","volume":"22","author":"Valencak","year":"1999","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mdh351_bb0085","first-page":"275","article-title":"Phase II trial of gemcitabine (Gem), 5-fluorouracil (5FU) and leucovorin (LV) in patients with unresectable or metastatic biliary (Bili) and gallbladder (GB) carcinoma: a North Central Center Treatment Group (NCCTG) study","volume":"22","author":"Jacobson","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0090","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","article-title":"Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: Results of a multicenter phase II study","volume":"19","author":"Gebbia","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0095","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/sj.bjc.6600543","article-title":"Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial","volume":"87","author":"Nehls","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh351_bb0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1016209901417","article-title":"Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas","volume":"20","author":"Kuhn","year":"2002","journal-title":"Invest New Drugs"},{"issue":"Abstr 2333","key":"10.1093\/annonc\/mdh351_bb0105","first-page":"20","article-title":"Gemcitabine and cisplatin in locally advanced or metastatic gallbladder and bile duct adenocarcinomas","volume":"146b","author":"Carraro","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008352123009","article-title":"Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer","volume":"12","author":"Penz","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0115","first-page":"3375","article-title":"Phase II trial of cisplatin, interferon \u03b1-2B, doxorubicin, and 5-fluorouracil for biliary tract cancer","volume":"7","author":"Patt","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh351_bb0120","first-page":"232","article-title":"Phase II trial of gemcitabine in gallbladder and biliary tract carcinomas","volume":"21","author":"Metzger","year":"1998","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mdh351_bb0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/sonc.2002.37380","article-title":"Review of gemcitabine in biliary tract carcinoma","volume":"29","author":"Scheithauer","year":"2002","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdh351_bb0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800050955","article-title":"Suppra additive effect of 2\u2032, 2\u2032-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines","volume":"44","author":"Faivre","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdh351_bb0135","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","article-title":"Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma","volume":"21","author":"Tempero","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh351_bb0140","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.20.6.1512","article-title":"Gemcitabine combined with oxaliplatin (Gemox) for advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study","volume":"20","author":"Louvet","year":"2002","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdh351_bb0145","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1359-6349(03)90081-4","article-title":"For the GERCOR (France) and the GISCAD (Italy). Gemcitabine versus GemOx (gemcitabine + oxaliplatin in nonresectable pancreatic adenocarcinoma: final results of the GERCOR\/GISCAD Intergroup phase III","volume":"1","author":"Louvet","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh351_bb0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh351_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2559.2000.00932.x","article-title":"Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver","volume":"37","author":"Shimonishi","year":"2000","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdh351_bb0160","first-page":"293","article-title":"A phase II study of gemcitabine and oxaliplatin (gemox) in advanced biliary adenocarcinoma (ABA). Final results","volume":"22","author":"Maindrault-Goebel","year":"2003","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419460523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419460523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/9\/1339\/19448364\/mdh351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:17:55Z","timestamp":1582197475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419460523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0923753419460523"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh351","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}